| 90 | | == Agenda == |
| 91 | | |
| 92 | | 1. [wiki:Research/DesignStudy/SteeringGroup/2020-06-05 Notes of last meeting and actions arising:] |
| 93 | | * **KL**: Set up series of meetings with leads at partner organisations to discuss preparation of R&D programme. |
| 94 | | * **Ongoing.** Need to step up the priority of this activity as we prepare the EPSRC proposal. |
| 95 | | * **KL/CB**: Consider meeting between Imperial (and other) ion-accelerator experts with the relevant experts in CLF. |
| 96 | | * **Stands.** This meeting is necessary and, probably, should include Strathclyde and Belfast. |
| 97 | | * **KL/KK** to collaborate on the development for a proposal for such a meeting on the timescale of November 2020. |
| 98 | | * **Stands.** Agenda item. |
| 99 | | * **KL** Send out diary invitation straight away to get it into the diary. |
| 100 | | * **Done.** |
| 101 | | |
| 102 | | 2. [raw-attachment:2020-07-03-Progress-update.pdf Update on progress]: KL \\ |
| 103 | | |
| 104 | | 3. Discussion of SG composition: KL/All |
| 105 | | |
| 106 | | 4. [https://epsrc.ukri.org/funding/calls/second-call-for-transformative-healthcare-technologies-pre-announcement-and-engagement-event/ EPSRC Transformative Healthcare Technologies call]: KL/All |
| 107 | | * Dealing with feedback from our 2019 submission: \\ |
| 108 | | "//Engagement with patients, clinicians and industry could have been strengthened//" |
| 109 | | - Patient engagement: |
| 110 | | - Actions taken to date; |
| 111 | | - Need for local action by partner; |
| 112 | | - Subsequent coordination |
| 113 | | - Clinician engagement: |
| 114 | | - Actions taken to date; |
| 115 | | - Need for local action by partner; |
| 116 | | - Subsequent coordination |
| 117 | | - Industrial engagement: |
| 118 | | - Actions taken to date; |
| 119 | | - Discussion of next steps |
| 120 | | * Slides to initiate discussion of: |
| 121 | | - Scope; |
| 122 | | - Initial discussion of work packages; |
| 123 | | - Stakeholders from whom we should be seeking support; |
| 124 | | * Next steps discussion |
| 125 | | |
| 126 | | 5. Follow-up Discussion of dedicated advanced diagnostics and instrumentation for the //in vitro// and //in vivo// end stations: KL/all |
| 127 | | |
| 128 | | 6. DONMs \\ |
| 129 | | * 04 Sep 2020; 10:00 BST |
| 130 | | |
| 131 | | 7. AoB \\ |
| 132 | | |
| 133 | | ---- |
